You are viewing the site in preview mode

Skip to main content

Advertisement

Table 3 Comparison of antibiotic susceptibility rates between the non-ESBL and ESBL groups

From: Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae

Antibiotics Non-ESBL group ESBL group p-value
  (n = 189) (n = 22)  
Penicillins    
 Ampicillin 44/131 (33.6) 0/18 (0.0) 0.003
 Piperacillin 40/103 (38.8) 0/11 (0.0) 0.008
Cephalosporins    
 Cefoxitin 127/130 (97.7) 16/18 (88.9) 0.112
 Cefotaxime 142/144 (98.6) 2/19 (10.5) <0.001
 Caftazidime 185/189 (97.9) 10/22 (45.5) <0.001
 Cefepime 186/189 (98.4) 10/22 (45.5) <0.001
β-lactam/β-latamase inhibitor combinations    
 Amoxicillin/clavulanate 107/131 (81.7) 12/18 (66.7) 0.205
 Piperacillin/tazobactam 177/187 (94.7) 18/21 (85.7) 0.131
Carbapenems    
 Imipenem 189/189 (100.0) 22/22 (100.0) NA
 Meropenem 189/189 (100.0) 22/22 (100.0) NA
Aminoglycosides    
 Gentamicin 158/188 (84.0) 16/22 (72.7) 0.228
 Tobramycin 87/102 (85.3) 9/11 (81.8) 0.670
 Amikacin 188/189 (99.5) 22/22 (100.0) 1.000
 Isepamicin 58/58 (100.0) 4/4 (100.0) NA
Fluoroquinolones    
 Ciprofloxacin 128/145 (88.3) 8/15 (53.3) 0.002
 Levofloxacin 42/44 (95.5) 5/7 (71.4) 0.086
Others    
 Trimethoprim/sulfamethoxazole 137/188 (72.9) 13/22 (59.1) 0.176
 Colistin 58/58 (100.0) 4/4 (100.0) NA
 Minocycline 47/58 (81.0) 4/4 (100.0) 1.000
  1. Data are no. (%) of cases
  2. ESBL extended-spectrum β-lactamase; NA not available